Related Experiment Videos
Immune checkpoints: A therapeutic target in triple negative breast cancer
Akhil Chawla1, Anne V Philips1, Gheath Alatrash2
1Department of Surgical Oncology; The University of Texas MD Anderson Cancer Center; Houston, TX USA.
Abstract:
Early clinical trials investigating monoclonal antibodies targeting the T-cell inhibitory receptor programmed cell death 1 (PD-1) and its ligand PD-L1 have shown efficacy in melanoma, non-small cell lung cancer and renal cell carcinoma. We recently demonstrated PD-L1 expression in 20% of triple negative breast cancers suggesting that targeting the PD-1/PD-L1 immune checkpoint may be an effective treatment modality in patients with this disease.
Insights
Monoclonal antibodies targeting programmed cell death 1 (PD-1) and its ligand PD-L1 show promise. PD-L1 expression in triple-negative breast cancer suggests this immune checkpoint may be an effective treatment.
Area of Science:
- Oncology
- Immunology
- Cancer Research
Background:
- Monoclonal antibodies targeting PD-1/PD-L1 have demonstrated efficacy in various cancers.
- Immune checkpoint inhibitors represent a significant advancement in cancer therapy.
Purpose of the Study:
- To investigate the potential of targeting the PD-1/PD-L1 immune checkpoint in triple-negative breast cancer (TNBC).
- To assess the prevalence of PD-L1 expression in TNBC as a predictive biomarker.
Main Methods:
- Analysis of PD-L1 expression in a cohort of triple-negative breast cancer patients.
- Review of early clinical trial data for PD-1/PD-L1 inhibitors in other cancer types.
Main Results:
- Programmed cell death ligand 1 (PD-L1) was expressed in 20% of triple-negative breast cancer cases.
- Prior studies show efficacy of PD-1/PD-L1 targeting in melanoma, lung, and renal cancers.
Conclusions:
- PD-L1 expression in TNBC suggests potential for immune checkpoint blockade therapy.
- Targeting the PD-1/PD-L1 pathway may offer a novel treatment strategy for TNBC patients.